By Colin Kellaher

Precigen Inc. on Friday said Germany's Merck KGaA elected to convert a $25 million note into common stock, raising its stake in the biopharmaceutical company to 14.8% from 11.6%.

The Germantown, Md., company issued the note to Merck in late 2018 as part of a deal in which Merck reassigned to Precigen its exclusive chimeric antigen receptor T-cell development rights.

Germany's Merck, which remains Precigen's second-largest shareholder, also received $150 million in stock as part of the transaction.

Precigen said the note would have otherwise converted in December.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 09, 2020 08:05 ET (12:05 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Merck KGaA (PK) Charts.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Merck KGaA (PK) Charts.